Butyrate is a fatty acid that colon bacteria make from fiber, sold as an oral dietary supplement for gut and metabolic health. Trials report narrow changes in bowel symptoms, weight without diabetes, blood fats, or a liver-fat score not from butyrate alone. Ulcerative colitis results conflict. Blood pressure moved in opposite directions, including a rise after blood-pressure drugs were stopped. Evidence that capsules extend life or prevent cancer is absent. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure | Below 120/80 mm Hg | Trials moved pressure in both directions |
| Fasting triglycerides | Below 100 mg/dL | Fell in one diabetes trial |
| Glycated hemoglobin | Below 5.4 percent | Longer glucose exposure |
| Fasting glucose | 75–90 mg/dL | Pairs with glycated hemoglobin |
| High-sensitivity C-reactive protein | Below 1.0 mg/L | Background inflammation |
| Body weight | Change from personal baseline | Non-diabetes trial outcome |
| Symptom score | Change from the person's own baseline | People with bowel symptoms |
| Fecal calprotectin | Change from the person's own baseline | If inflammatory bowel disease is already diagnosed, through usual care |
Cadence: Baseline before the first dose for seated morning blood pressure, body weight, and fasting triglycerides, glucose, and glycated hemoglobin. Blood pressure again at about 4 weeks. Weight, triglycerides, glucose, and glycated hemoglobin at 12 weeks, then every 6–12 months if use continues.